Omacetaxine mepesuccinate (brand name Synribo) is a chemotherapy drug used to treat adults with chronic myelogenous leukemia (CML). It is a protein synthesis inhibitor that helps to reduce the number of cancer cells in the body. It is given as an injection under the skin (subcutaneously) and is usually taken once a day for up to 18 weeks. Common side effects include fatigue, nausea, and diarrhea.
Omacetaxine mepesuccinate, also known by the trade name Synribo, is a medication used to treat chronic myeloid leukemia (CML) in adults who are resistant to or intolerant of other treatments. It is a chemotherapy medication that works by interfering with the process of protein synthesis in cancer cells.
Here's a summary of Omacetaxine mepesuccinate:
- Type of drug: Chemotherapy medication
- Uses: Treatment of chronic myeloid leukemia (CML) in adults resistant to or intolerant of other treatments
- Mechanism of action: Inhibits protein synthesis in cancer cells
Important Note: Omacetaxine mepesuccinate is a prescription medication and should only be used under the supervision of a qualified healthcare professional.
Information about a medication should not be used as a substitute for professional medical advice. Always consult with your doctor or other qualified healthcare provider about any questions you may have regarding a medical condition or treatment.